Publique en esta revista
Información de la revista
Vol. 6. Núm. A.
Actualización y futuro del óxido nítrico en el tratamiento de la enfermedad cardiovascular
Páginas 31A-40A (Marzo 2006)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 6. Núm. A.
Actualización y futuro del óxido nítrico en el tratamiento de la enfermedad cardiovascular
Páginas 31A-40A (Marzo 2006)
Actualización y futuro del óxido nítrico en el tratamiento de la enfermedad cardiovascular
Acceso a texto completo
Fundamentos del tratamiento farmacológico actual de la cardiopatía isquémica
Current Foundations of the Pharmacological Treatment of Ischemic Heart Disease
Visitas
...
Rut Andrea, Neus Bellera, Pablo Loma-Osorio, Magda Heras??
Autor para correspondencia
mheras@clinic.ub.es

Correspondencia: Dra. M. Heras. Servicio de Cardiología. Hospital Clínic. Villarroel, 170. 08036 Barcelona. España.
Servicio de Cardiología. Hospital Clínic. IDIBAPS. Barcelona. España
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

El tratamiento de la cardiopatía isquémica ha avanzado en paralelo al conocimiento de las bases fisiopatológicas de la enfermedad. La demostración de la trombosis coronaria como causa inmediata del infarto agudo de miocardio, el papel de la activación de la angiotensina en el remodelado miocárdico, la importancia del sistema adrenérgico en la función ventricular y el valor del control de las concentraciones de colesterol han sido los cuatro pilares fundamentales sobre los que se han desarrollado las estrategias terapéuticas que utilizamos en la actualidad. En este artículo se revisan brevemente los fármacos antitrombóticos, los bloqueadores beta, los bloqueadores del sistema renina-angiotensina-aldosterona y las estatinas.

Palabras clave:
Inhibidores agregación plaquetaria
Anticoagulantes
Inhibidores angiotensina
Bloqueadores beta
Estatinas

The treatment of ischemic heart disease has advanced in parallel with increasing knowledge of the pathophysiological causes of the disease. The therapeutic strategies we use today rest on four central pillars: demonstration of coronary thrombosis as the immediate cause of acute myocardial infarction, the influence of the renin-angiotensin-aldosterone system on ventricular remodeling, the significance of the adrenergic system for ventricular function, and the prognostic value of reducing the cholesterol level. This article contains a brief review of antithrombotic drugs, beta-blockers, drugs that block the renin-angiotensin- aldosterone system, and statins.

Key words:
Platelet aggregation inhibitors
Anticoagulants
Angiotensin inhibitors
Beta-blockers
Statins
El Texto completo está disponible en PDF
Bibliografía
[1.]
ISIS-2 (Second International Study of Infarct survival) Collaborative Group.
Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17.187 cases of suspected acute myocardial infarction: ISIS-2.
Lancet, 2 (1988), pp. 349-360
[2.]
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
BMJ, 324 (2002), pp. 71-86
[3.]
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. N Engl J Med. 2001;345:494-502. Fe de erratas en: N Engl J Med. 2001;345:1716 y N Engl J Med. 2001;345: 1506.
[4.]
J.A. Cairns, P. Theroux, H.D. Lewis Jr, M. Ezekowitz, T.W. Meade.
Antithrombotic agents in coronary artery disease.
Chest, 119 (2001), pp. 228S-252S
[5.]
P.M. Ridker, J.E. Manson, J.M. Gaziano, J.E. Buring, C.H. Hennekens.
Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial.
Ann Intern Med, 114 (1991), pp. 835-839
[6.]
M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. López-Sendón, G. Montalescot, P. Theroux, et al.
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
N Engl J Med, 352 (2005), pp. 1179-1189
[7.]
CAPRIE Steering Committee.
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events.
Lancet, 348 (1996), pp. 1329-1339
[8.]
A. Schomig, F.J. Neumann, A. Kastrati, H. Schuhlen, R. Blasini, M. Hadamitzky, et al.
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
N Engl J Med, 334 (1996), pp. 1084-1089
[9.]
G.W. Stone, C.L. Grines, D.A. Cox, E. García, J.E. Tcheng, J.J. Griffin, et al.
Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
N Engl J Med, 346 (2002), pp. 957-966
[10.]
G. Montalescot, P. Barragan, O. Wittenberg, P. Ecollan, S. Elhadad, P. Villain, et al.
ADMIRAL Investigators. Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
N Engl J Med, 344 (2001), pp. 1895-1903
[11.]
D. Antoniucci, A. Rodriguez, A. Hempel, R. Valenti, A. Migliorini, F. Vigo, et al.
A ramdomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.
J Am Coll Cardiol, 42 (2003), pp. 1879-1885
[12.]
M.L. Simoons.
The Gusto IV-ACS investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
Lancet, 357 (2001), pp. 1915-1924
[13.]
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina.
The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.
Circulation, 97 (1998), pp. 2386-2395
[14.]
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.
N Engl J Med, 338 (1998), pp. 1488-1497
[15.]
A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina.
The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators.
N Engl J Med, 338 (1998), pp. 1498-1505
[16.]
Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
N Engl J Med, 339 (1998), pp. 436-443
[17.]
ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41.299 cases of suspected acute myocardial infarction.
Lancet, 339 (1992), pp. 753-770
[18.]
GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12.490 patients with acute myocardial infarction.
Lancet, 336 (1990), pp. 65-71
[19.]
The GUSTO investigators.
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
N Engl J Med, 329 (1993), pp. 673-682
[20.]
Assessment of Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators.
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
[21.]
L. Wallentin, P. Goldstein, P.W. Armstrong, C.B. Granger, A.A. Adgey, H.R. Arntz, et al.
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT- 3 PLUS) randomized trial in acute myocardial infarction.
Circulation, 108 (2003), pp. 135-142
[22.]
W. Klein, A. Buchwald, E.S. Hillis, S. Monrad, G. Sanz, A.G. Graham, et al.
Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC).
Circulation, 96 (1997), pp. 61-68
[23.]
E.M. Antman, M. Cohen, D. Radley, C. McCabe, J. Rush, J. Premmereur, et al.
Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11BESSENCE meta-analysis.
Circulation, 100 (1999), pp. 1602-1608
[24.]
H. White.
Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial.
Lancet, 358 (2001), pp. 1855-1863
[25.]
ISIS-1 (First International Study of Infarct Survival) collaborative group.
Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1.
Lancet, II (1986), pp. 57-66
[26.]
J. López-Sendón, K. Swedberg, J. McMurray, J. Tamargo, A.P. Maggioni, H. Dargie, et al.
Expert consensus document on beta-adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology.
Eur Heart J, 25 (2004), pp. 1341-1362
[27.]
R. Roberts, W.J. Rogers, H.S. Mueller, C.T. Lambrew, D.J. Diver, H.C. Smith, et al.
Immediate versus deferred betablockade follo-wing thrombolytic therapy in patients with acute myocardial infarction (TIMI) IIB study.
Circulation, 83 (1991), pp. 422-437
[28.]
S.J. Kernis, K.J. Harjai, G.W. Stone, L.L. Grines, J.A. Boura, W.W. O’Neill, et al.
Does beta-bloquer therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? A pooled analysis from the primary angioplasty in myocardial infarction-2 (PAMI-2), No surgery on-site (noSOS), stent PAMI and Air PAMI trials.
Circulation, 108 (2003), pp. 1237-1246
[29.]
S. Gottlieb, R. McCarter, R. Vogel.
Effect of beta-blockade on mortality among high risk patients after myocardial infarction.
N Engl J Med, 338 (1998), pp. 489-497
[30.]
S. Yusuf, J. Witte, L. Friedman.
Overview of results of randomized trials in heart disease: unstable angina, heart failure, primary prevention with aspirin and risk factor modifications.
JAMA, 260 (1988), pp. 2259-2263
[31.]
S. Yusuf, J. Lessem, P. Jha, E. Lonn.
Primary and secondary prevention of myocardial infarction and strokes. An update of randomly allocated controlled trials.
J Hypertens, 11 (1993), pp. S61-S73
[32.]
M.E. Bertrand, M.L. Simoons, K.A. Fox, L.C. Wallentin, C.W. Hamm, E. McFadden, et al.
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology.
Eur Heart J, 23 (2002), pp. 1809-1840
[33.]
N. Freemantle, J. Cleland, P. Young, J. Mason, J. Harrison.
Beta blockade after myocardial infarction. Systematic review and meta regression analysis.
BMJ, 318 (1999), pp. 1730-1737
[34.]
F. Van de Werf, D. Ardissino, A. Betriu, D.V. Cokkinos, E. Falk, K.A. Fox, et al.
Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.
Eur Heart J, 24 (2003), pp. 28-66
[35.]
The beta-blocker pooling project research group.
The beta-blocker pooling project. Subgroup findings from randomized trials in postinfarction patients.
Eur Heart J, 9 (1988), pp. 8-16
[36.]
H.J. Dargie, I. Ford, K.M. Fox.
Total ischaemic burden European trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group.
Eur Heart J, 17 (1996), pp. 104-112
[37.]
N. Rehnqvist, P. Hjemdahl, E. Billing, I. Bjorkander, S.V. Eriksson, L. Forslund, et al.
Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. angina prognosis study in Stockholm.
Cardiología, 40 (1995), pp. S301
[38.]
S. Savonitto, D. Ardissino, K. Egstrup, K. Rasmussen, E.A. Bae, T. Omland, et al.
Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the international multicenter angina exercise (IMAGE) study.
J Am Coll Cardiol, 27 (1996), pp. 311-316
[39.]
S. Yusuf, P. Held, C. Furberg.
Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies.
Am J Cardiol, 67 (1991), pp. 1295-1297
[40.]
R.S. Gibson, W.E. Boden, P. Theroux, H.D. Strauss, C.M. Pratt, M. Gheorghiade, et al.
Diltiazem and reinfarction in patients with non Q-wave myocardial infarction: results of a double-blind, randomized, multi-center trial.
N Engl J Med, 315 (1986), pp. 423
[41.]
W.E. Boden, W.H. van Gilst, R.G. Scheldewaert, I.R. Starkey, M.F. Carlier, D.G. Julian, et al.
Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis.
Lancet, 355 (2000), pp. 1751-1756
[42.]
N.L.R.G. Smith, G.E. Reiberge, B.M. Psaty, S.R. Heckbert, D.S. Siscovick, J.L. Ritchie, et al.
Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina.
J Am Coll Cardiol, 32 (1998), pp. 1305-1311
[43.]
J.T.J. Lubsen, J.G. Tijssen.
Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT).
Am J Cardiol, 60 (1987), pp. 18A-25A
[44.]
P.Y.S. Held, C.D. Furberg.
Calcium channel blockers in acute myocardial infarction and unstable angina: an overview.
BMJ, 299 (1989), pp. 1187-1192
[45.]
E. Braunwald.
Mechanism of action of calcium-channel-blocking agents.
N Engl J Med, 307 (1982), pp. 1618-1627
[46.]
C.D. Furberg, B.M. Psaty, J.V. Meyer.
Nifedipine: dose-related increase in mortality in patients with coronary heart disease.
Circulation, 92 (1995), pp. 1326-1331
[47.]
J.M. Detry, P. Sellier, S. Pennaforte, D. Cokkinos, H. Dargie, P. Mathes.
Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.
Br J Clin Pharmacol, 37 (1994), pp. 279-288
[48.]
S. Dalla-Volta, G. Maraglino, P. Della-Valentina, P. Viena, A. Desideri.
Comparison of trimetazidine with nifedipine in effort angina: a double blind cross over study.
Cardiovasc Drugs Ther, 4 (1990), pp. 853-860
[49.]
S. Levy, The group of South of France Investigators.
Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease.
Am J Cardiol, 76 (1995), pp. B12-B16
[50.]
M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown Jr, T.E. Cuddy, et al.
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
N Engl J Med, 327 (1992), pp. 669-677
[51.]
The AIRE Study Investigators.
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.
Lancet, 342 (1993), pp. 821-828
[52.]
L. Kober, C. Torp-Pedersen, J.E. Carlsen, H. Bagger, P. Eliasen, K. Lyngborg, et al.
A clinical trial of the ACE inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. TRACE Study Group.
N Engl J Med, 333 (1995), pp. 1670-1676
[53.]
K. Swedberg, P. Held, J. Kjekshus, K. Rasmussen, L. Ryden, H. Wedel.
Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the CONSENSUS II.
N Engl J Med, 327 (1992), pp. 678-684
[54.]
GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction.
Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico.
Lancet, 343 (1994), pp. 1115-1122
[55.]
E. Ambrosini, C. Borghi, B. Magnani.
The effect of the ACE inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.
N Engl J Med, 332 (1995), pp. 80-85
[56.]
ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.
Lancet, 345 (1995), pp. 669-685
[57.]
CCS-1 Collaborative Group.
Oral captopril versus placebo among 14,062 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chinese Cardiac Study (CCS-1) Collaborative Group.
Chin Med J (Engl), 110 (1997), pp. 834-838
[58.]
S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais.
Effects of an ACE inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med, 342 (2000), pp. 145-153
[59.]
K.M. Fox, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study).
Lancet, 362 (2003), pp. 782-788
[60.]
K. Dickstein, J. Kjekshus, OPTIMAAL Steering Committee of the OPTIMAAL Study Group.
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.
Lancet, 360 (2002), pp. 752-760
[61.]
M.A. Pfeffer, J.J. McMurray, E.J. Velázquez, J.L. Rouleau, L. Kober, A.P. Maggioni, et al.
Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular disfunción, or both.
N Engl J Med, 349 (2003), pp. 1893-1906
[62.]
B. Pitt, H. White, J. Nicolau, F. Martinez, M. Gheorghiade, M. Aschermann, et al.
EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
J Am Coll Cardiol, 46 (2005), pp. 425-431
[63.]
P.M. Ridker, C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose, C.H. McCabe, et al.
Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE ITTIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy.
N Engl J Med, 352 (2005), pp. 20-28
[64.]
S. Tsimikas, J.L. Witztum, E.R. Miller, W.J. Sasiela, M. Szarek, A.G. Olsson, et al.
Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Circulation, 110 (2004), pp. 1406-1412
[65.]
J.A. De Lemos, M.A. Blazing, S.D. Wiviott, E.F. Lewis, K.A. Fox, H.D. White, et al.
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
JAMA, 292 (2004), pp. 1307-1316
[66.]
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[67.]
M.A. Pfeffer, F.M. Sacks, L.A. Moye, L. Brown, J.L. Rouleau, L.H. Hartley, et al.
Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. CARE Investigators.
Am J Cardiol, 76 (1995), pp. C98-C106
[68.]
D.G. Julian, M.E. Bertrand, A. Hjalmarson, K. Fox, L. Simoons, L. Ceremuzynski, et al.
Guidelines for management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology.
Eur Heart J, 18 (1997), pp. 394-413
Copyright © 2006. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?